Business Today

AstraZeneca shares tank 11% on termination notice for Meronem

AstraZeneca Pharma stock plunged almost 11 per cent in trade on Thursday as it will stop selling anti-bacterial drug Meronem in India following a global deal by its UK parent to sell its small molecule antibiotics business to Pfizer Inc.

twitter-logo PTI   New Delhi     Last Updated: August 26, 2016  | 08:13 IST
AstraZeneca shares tank 11% on termination notice for Meronem
Photo: Reuters

AstraZeneca Pharma stock plunged almost 11 per cent in trade on Thursday as it will stop selling anti-bacterial drug Meronem in India following a global deal by its UK parent to sell its small molecule antibiotics business to Pfizer Inc.

The scrip tanked 7.93 per cent to Rs 1,050 on BSE.

ALSO READ: Telecom stocks out of coverage area, but experts see 40% upside on Bharti Airtel, Idea

Meronem is anti-bacterial used for the treatment of serious infections in hospitalised patients.

The company has received a notice from AstraZeneca UK for termination of distribution arrangements for Meronem in India, AstraZeneca Pharma India said in a regulatory filing yesterday.


ALSO READ: Three sectors that have gained up to 50% in last one year

"The current distribution arrangement for Meronem in India will terminate in six months," it added.

This is a result of a global agreement by AstraZeneca PLC to sell the development and commercialisation rights to Pfizer Inc of its late stage small molecule antibiotics business, it said.

Youtube
  • Print

  • COMMENT
BT-Story-Page-B.gif
A    A   A
close